Literature DB >> 22490293

[Clinical significance of CC3/TIP30 expression in breast carcinoma and its correlation with HER-2/neu].

Qi-di Huang1, Xiao-qu Hu, Li Wan, Guo-hui Gao, Shu-rong Zheng, Jie You, Gui-long Guo.   

Abstract

OBJECTIVE: To explore the clinical significance of CC3/TIP30 protein's expression in breast carcinoma and its correlation with HER-2/neu.
METHODS: The expression of CC3/TIP30 and HER-2/neu protein was detected in 112 breast cancer tissues which was collected from January 2004 to January 2005 by immunohistochemistry and the relationship with clinic pathological parameters and prognosis was analyzed. Small interfering RNA (siRNA) which target to knock out CC3/TIP30 were transfected into SK-BR-3 cells. Real-time PCR were used to detect the level of CC3/TIP30 and HER-2/neu mRNA.
RESULTS: The results of immunohistochemistry showed CC3/TIP30 protein was correlated with TNM stage, lymph node status, HER-2 status and molecule classification (P = 0.048, 0.019, 0.027, 0.011), but there was no association with age, tumor size, estrogen receptor and progesterone receptor. Real-time PCR results revealed that CC3/TIP30 siRNA down-regulation the level of its mRNA, accompanied by a decline in the expression of HER-2/neu gene mRNA, the difference was statistically significant (F = 56.797, P = 0.000; F = 165.101, P = 0.000). In addition, Kaplan-Meier curves of disease-specific survival analysis showed a marked difference in the subtype of HER-2 protein positive between CC3/TIP30 positive group and negative group (χ(2) = 10.732, P = 0.001).
CONCLUSIONS: The loss of CC3/TIP30 is related to occurrence and development in breast cancer, suggesting early onset of metastasis and recurrence. Perhaps CC3/TIP30 can be considered as a sub-typing indicator in HER-2 positive breast cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22490293

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  4 in total

1.  Contribution of TIP30 to chemoresistance in laryngeal carcinoma.

Authors:  M Zhu; F Yin; L Yang; S Chen; R Chen; X Zhou; W Jing; X Fan; R Jia; H Wang; H Zheng; J Zhao; Y Guo
Journal:  Cell Death Dis       Date:  2014-10-16       Impact factor: 8.469

2.  Overexpression of TIP30 inhibits the growth and invasion of glioma cells.

Authors:  Yingying Hu; Fengsheng Chen; Feiye Liu; Xinhui Liu; Na Huang; Xiaoli Cai; Yi Sun; Aimin Li; Rongcheng Luo
Journal:  Mol Med Rep       Date:  2015-11-27       Impact factor: 2.952

3.  Tat-Interacting Protein 30 (TIP30) Expression Serves as a New Biomarker for Tumor Prognosis: A Systematic Review and Meta-Analysis.

Authors:  Tao Xu; Zhichao Jin; Yuan Yuan; Honggang Zheng; Conghuang Li; Wei Hou; Qiujun Guo; Baojin Hua
Journal:  PLoS One       Date:  2016-12-30       Impact factor: 3.240

4.  Reduction of Tat-interacting Protein 30 Expression Could be a Prognostic Marker in Bladder Urothelial Cancer.

Authors:  Ye-Ping Li; Jian-Fang Zhu; Ka-Te Huang; Rong-Rong Wang; Bing Cai; Hui Xie; Hong-De Chen
Journal:  Chin Med J (Engl)       Date:  2018-01-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.